Australia: TGA Australia Unveils Revised Australian Clinical Trial Handbook

Guidance on conducting clinical trials in Australia using 'unapproved' therapeutic goods

On March 15, 2018, the Therapeutic Goods Administration (TGA) of Australia released revised (version 2.0) of the Australian Clinical Trial Handbook. This handbook provides guidance on the legislative, regulatory and good clinical practice (GCP) requirements when conducting clinical trials in Australia using 'unapproved' therapeutic goods40. This revision, the first major change to the document since its inception in 2006, aims to bring the information in line with the current regulatory environment and to reflect current practices and meet government accessibility requirements.

The revised version 2.0 of the guidance covers all aspects of clinical trials, from different phases to Australia-specific aspects, for getting a study approved. The guidance aims to help sponsors, ethics committees, investigators and other groups understand their roles and obligations. New sections in the document include information on the advertising of experimental drugs and the retrieval and destruction of unapproved medicines. Other sections, such as a discussion of the merits of running trial extensions, are covered in more detail than in the earlier version.

This handbook assists trial sponsors, Human Research Ethics Committees (HRECs), investigators and approving authorities (institutions) to understand their roles and responsibilities under the therapeutic goods legislation.

This is a 55-page document guiding trial sponsors and principal investigators, Human Research Ethics Committees (HRECs), and approving authorities (institutions in which the trial is being conducted) on unapproved therapeutic goods, covering medicines, medical devices and in vitro diagnostics, biologics and other types of products.

Clinical trials involving therapeutic goods

According to the handbook, clinical trials involving therapeutic goods are generally undertaken to assess the effects, efficacy, performance and/or safety of the product. It is therefore necessary that clinical trials are conducted using appropriate exper al, all parties should be satisfied that the rights, safety and well-being of trial participants will be protected and that clinical trial data generated will be reliable and robust. To achieve such objectives, clinical trials involving 'unapproved' therapeutic goods must be conducted in accordance with:

  • The requirements of the Therapeutic Goods Legislation
  • The principles that have their origin in the World Medical Association Declaration of Helsinki
  • The National Statement on Ethical Conduct in Human Research (the National Statement) as in force from time to time
  • The relevant Good Clinical Practice (GCP) guideline
  • Other relevant requirements of Commonwealth and/or state and territory legislation
  • Site specific requirements

Determining the type of therapeutic good

The handbook describes the regulation of three main types of therapeutic goods:

  1. Medicines (including prescription medicines, over-the-counter medicines and complementary medicines)
  2. Medical devices (including in vitro diagnostic medical devices (IVDs))
  3. Biologicals (including human cell and tissue-based therapeutic goods, or live animal cells, tissues and organs)

The agency also regulates a very limited fourth type of goods known as other therapeutic goods (OTGs) examples of which include sterilants, disinfectants and tampons.

Figure 1: Four types of therapeutics goods regulated by the TGA

Determining if the product is 'unapproved'

According to the Australia Regulations, Therapeutic goods must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported into, exported from or supplied in Australia unless otherwise subject to an exemption, approval or authority under the Therapeutic Goods Act 198941. In this new clinical trial handbook, the reference to 'unapproved' therapeutic goods is an abbreviated expression which is intended to include:

  • Any medicine not included in the ARTG, such as any new formulation, strength or size, dosage form, name, indications, directions for use or type of container of a medicine already in the ARTG
  • Any medical device (including an in vitro diagnostic device (IVD)) not included in the ARTG, such as any new sponsor, manufacturer, device nomenclature system code, classification or unique product identifier (for certain classes of medical devices only) of a medical device already in the ARTG

    • Any in-house IVD medical device, used for the purpose of a clinical trial, where the laboratory providing the in-house IVD is unable to comply with the regulatory requirements for in-house IVDs (a laboratory developed test used for research purposes where results of such testing are not being not being used in patient diagnosis, treatment or management decisions would not be considered an in-house IVD)
  • Any biological not included in the ARTG such as:

    • Any new applicable standards, intended clinical use or principal manufacturer of a Class 1 or 2 biological already in the ARTG
    • Any new product name, dosage form, formulation or composition, therapeutic indication, type of container or principal manufacturer of a Class 3 or 4 biological already in the ARTG
  • Therapeutic goods already included in the ARTG to be used in a manner not covered by the existing entry in the ARTG.

CTN and CTX Scheme

This handbook describes the two schemes under which clinical trials involving 'unapproved' therapeutic goods may be conducted in Australia:

  1. Clinical Trial Notification (CTN) scheme
  2. Clinical Trial Exemption (CTX) scheme

The CTN and CTX schemes aim to provide considerable benefits by providing the momentum to research and develop new therapeutic goods locally and facilitate early patient access to new therapeutic developments42. The main difference between the CTN and CTX schemes is agency's level of involvement in reviewing data about the therapeutic goods before the clinical trial commences.

Clinical trials that do not involve the use of 'unapproved' therapeutic goods are not subject to the requirements of the CTN and CTX schemes.

Role of trial sponsors

According to the handbook, all clinical trials conducted in Australia must have a trial sponsor who is an Australian entity (an overseas company cannot be the sponsor of a trial in Australia). Sponsors of trials under the CTN or CTX schemes may include individuals, companies, institutions, or organizations. The trial sponsor is responsible for the initiation, management and financing (or arranging finance) of the trial and carries the medico-legal responsibility associated with its conduct. The Australian trial sponsor is the entity responsible for submitting a CTN or CTX to the agency.

The handbook also defines detailed roles of other stakeholders like:

  1. Role of Human Research Ethics Committees (HRECs)
  2. Role of approving authorities
  3. Role of principal investigators
  4. Role of TGA, the agency

Safety Reporting to the Agency

The handbook lays down the timeframes for reporting of Safety Information from the clinical trials:

  • For Single case events from Australian sites;
  • Significant safety issues and overseas regulatory action; and
  • Other Report Types

Advertising 'unapproved' therapeutic goods

The handbook says that it is an offence to advertise any therapeutic good that has not been included in the ARTG under the Therapeutic Goods Act, 1989. While the trial sponsor can promote their trial in the public domain, they cannot specifically mention the name of the therapeutic good being used in the trial. Further, any advertisement for a clinical trial should be approved by the Human Research Ethics Committees (HREC) reviewing the trial.

Conclusion:

TGA's revised clinical trial handbook provides guidance on the legislative, regulatory and good clinical practice (GCP) requirements when conducting clinical trials in Australia using 'unapproved' therapeutic goods. The revisions, which are the first major changes to the document since 2006, bring the information in line with the current regulatory environment and provide further details about how to set up and run clinical trials in Australia.

Footnotes

40. https://www.tga.gov.au/sites/default/files/australian-clinical-trial-handbook-01.pdf

41. https://www.legislation.gov.au/Series/C2004A03952/

42. https://www.tga.gov.au/book-page/ctn-and-ctx-schemes

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Corrs Chambers Westgarth
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Corrs Chambers Westgarth
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions